Henry Schein Inc. has entered into an exclusive distribution agreement with CytoChip Inc. for the CitoCBC® system, a CLIA-waived, FDA 510(k)-cleared cartridge-based hematology analyzer. Under the agreement, Henry Schein will distribute the CitoCBC system to healthcare providers in the United States, specifically in ambulatory care settings such as physician offices, urgent care centers, and critical access hospitals with 25 patient beds or fewer. The agreement does not include long-term care or acute care facilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Henry Schein Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115495488) on January 15, 2026, and is solely responsible for the information contained therein.